FIL Ltd cut its holdings in Grifols, S.A. (NASDAQ:GRFS) by 9.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,341,668 shares of the biotechnology company’s stock after selling 348,069 shares during the period. FIL Ltd owned 0.24% of Grifols, worth $70,609,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of GRFS. Wells Fargo & Company MN increased its stake in shares of Grifols, by 2.9% in the first quarter. Wells Fargo & Company MN now owns 171,871 shares of the biotechnology company’s stock worth $3,244,000 after purchasing an additional 4,842 shares during the period. Comerica Bank increased its stake in shares of Grifols, by 1.0% in the first quarter. Comerica Bank now owns 18,817 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 185 shares during the period. Ameriprise Financial Inc. increased its stake in shares of Grifols, by 16.1% in the first quarter. Ameriprise Financial Inc. now owns 13,277 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 1,839 shares during the period. Parametric Portfolio Associates LLC increased its stake in shares of Grifols, by 5.4% in the first quarter. Parametric Portfolio Associates LLC now owns 643,696 shares of the biotechnology company’s stock worth $12,150,000 after purchasing an additional 33,206 shares during the period. Finally, Oxford Asset Management increased its stake in shares of Grifols, by 381.0% in the first quarter. Oxford Asset Management now owns 103,868 shares of the biotechnology company’s stock worth $1,961,000 after purchasing an additional 82,272 shares during the period. Institutional investors and hedge funds own 21.93% of the company’s stock.

Grifols, S.A. (NASDAQ:GRFS) traded up 0.747% during trading on Friday, hitting $20.915. The stock had a trading volume of 77,868 shares. Grifols, S.A. has a 12-month low of $14.27 and a 12-month high of $22.83. The stock has a 50 day moving average price of $20.69 and a 200 day moving average price of $20.38. The company has a market capitalization of $28.58 billion, a price-to-earnings ratio of 42.727 and a beta of 1.00.

ILLEGAL ACTIVITY WARNING: “Grifols, S.A. (GRFS) Stake Lowered by FIL Ltd” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/22/grifols-s-a-grfs-stake-lowered-by-fil-ltd.html.

A number of equities analysts have recently commented on GRFS shares. Bank of America Corporation reiterated a “buy” rating on shares of Grifols, in a research note on Tuesday, July 4th. BidaskClub upgraded Grifols, from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research upgraded Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Tuesday, July 4th. Finally, Goldman Sachs Group, Inc. (The) lowered Grifols, from a “buy” rating to a “neutral” rating in a research note on Friday, June 30th. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Grifols, presently has a consensus rating of “Hold” and a consensus target price of $24.00.

Grifols, Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Institutional Ownership by Quarter for Grifols, (NASDAQ:GRFS)

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.